SMO and melanoma: We also demonstrate that NVP-LDE-225, a small molecule SMO inhibitor already in clinical trials in other solid tumors, inhibits the hedgehog pathway effectively and has antitumor activity against B-RAF mutant melanoma both in vitro and in vivo.